SEP 9, 2026 · PHASE 2 TRIAL
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
ClinicalTrials.gov
This is a Phase 2 trial registry record with no results posted; enrollment is complete but outcomes have not yet been reported or analysed.
Reported
Planned enrollment (actual)39
PhasePhase 2
Primary outcome measureObjective response rate (ORR)